检索结果-南通市图书馆

ETV4在胃肠道间质瘤中的表达及其临床意义

在线全文

学校读者我要写书评

暂无评论

中国医科大学学报 2020年第4期49卷 321-325,330页

作者：徐丹邱雪杉中国医科大学附属第一医院病理科沈阳110001 中国医科大学基础医学院病理学教研室沈阳110122

目的探讨ETV4在胃肠道间质瘤(GIST)组织中表达及其与危险度等临床病理特征的关系,以及ETV4与GIST中C-KIT,血小板衍生生长因子受体α(PDGFR-α)基因突变的关系。方法采用免疫组化方法检测ETV4在91例GIST中的表达情况,采用直接测序法对91... 详细信息

目的探讨ETV4在胃肠道间质瘤(GIST)组织中表达及其与危险度等临床病理特征的关系,以及ETV4与GIST中C-KIT,血小板衍生生长因子受体α(PDGFR-α)基因突变的关系。方法采用免疫组化方法检测ETV4在91例GIST中的表达情况,采用直接测序法对91例GIST病例进行测序。结果在GIST组织中,有39例(42.9%)ETV4呈强阳性表达,34例(37.4%)呈中等阳性表达。ETV4表达与患者肿瘤大小,核分裂像,Ki67增殖指数,肝转移有关(P<0.05)。ETV4表达水平与危险度呈显著正相关(r=0.387,P<0.001);此外,ETV4表达水平与C-KIT基因突变呈显著正相关(r=0.324,P=0.008),ETV4表达水平与突变型GIST呈显著正相关(r=0.325,P=0.005)。结论ETV4转录因子可以作为临床判定GIST生物学行为的重要指标,并且可能会成为治疗GIST的新靶点。

关键词：胃肠道间质瘤 ETV4 危险度 C-KIT 血小板衍生生长因子受体α

在线全文

学校读者我要写书评

暂无评论

睾丸非精原细胞性生殖细胞肿瘤68例

中国肿瘤临床 2006年第11期33卷 651-653页

作者：胡滨付成丘雪杉中国医科大学基础医学院病理学教研室沈阳市110001 辽宁省肿瘤医院泌尿外科

目的:总结原发性睾丸非精原细胞性生殖细胞肿瘤(NSGCT)的诊断与治疗体会。方法:回顾性分析收治的68例NSGCT临床资料。胚胎癌35例,畸胎瘤11例,卵黄囊瘤3例,绒毛膜上皮癌6例,混合性生殖细胞瘤13例。睾丸无痛性肿大为其主要临床表现。在根... 详细信息

目的:总结原发性睾丸非精原细胞性生殖细胞肿瘤(NSGCT)的诊断与治疗体会。方法:回顾性分析收治的68例NSGCT临床资料。胚胎癌35例,畸胎瘤11例,卵黄囊瘤3例,绒毛膜上皮癌6例,混合性生殖细胞瘤13例。睾丸无痛性肿大为其主要临床表现。在根治性睾丸切除基础上采用腹膜后淋巴结清扫术(RPLND)及化疗等综合治疗措施。结果:全组患者中随访63例,失访5例。睾丸肿瘤的B超诊断优于CT,腹膜后淋巴结的CT诊断优于B超。3、5年生存率与国内外报道相似。结论:NSGCT在根治性睾丸切除基础上采用RPLND及化疗等综合治疗措施,疗效满意。B超和CT为其诊断和临床分期的主要手段。肿瘤标记物对治疗以及预后判断有一定参考价值。

关键词：非精原细胞性生殖细胞肿瘤诊断治疗

不断肌肉、不断肋骨、微创小切口开胸手术切除多发性硬化性肺细胞瘤1例

在线全文

学校读者我要写书评

暂无评论

中国微创外科杂志 2017年第3期17卷 285-288页

作者：张军邱雪杉中国医科大学附属第一医院中国医科大学肺癌中心中国医科大学肿瘤研究所肿瘤分子靶向治疗研究室沈阳110001 中国医科大学病理学教研室沈阳110001

硬化性肺细胞瘤现归类于肺肿瘤之腺瘤,是肺良性肿瘤。多发性硬化性肺细胞瘤较为少见(罕见)。2012年8月,我们对1例59岁女性施行"不断肌肉、不断肋骨、微创小切口开胸手术"(minimally invasive small incision,muscle-and rib-sparing tho... 详细信息

硬化性肺细胞瘤现归类于肺肿瘤之腺瘤,是肺良性肿瘤。多发性硬化性肺细胞瘤较为少见(罕见)。2012年8月,我们对1例59岁女性施行"不断肌肉、不断肋骨、微创小切口开胸手术"(minimally invasive small incision,muscle-and rib-sparing thoracotomy,mi MRST,简称微创小切口开胸手术),对右肺下叶5 cm占位行右肺下叶切除术,右肺中叶0.7 cm占位行楔形切除术,术后病理诊断多发性硬化性肺细胞瘤,术后随访4年,无复发、转移。

关键词：肺肿瘤硬化性肺细胞瘤肺硬化性血管瘤不断肌肉、不断肋骨、微创小切口开胸手术肺叶切除术

Heparanase Expression Correlates with Angiogenesis and Lymphangiogenesis in Human Lung Cancer

在线全文

学校读者我要写书评

暂无评论

中国肺癌杂志 2009年第8期12卷 864-867页

作者： Qingfu ZHANG Jian MING Yang LI Siyang ZHANG Bo LI xueshan qiu Enhua WANG Department of Pathology College of Basic Medical Sciences China Medical University and Department of Pathology the First Affiliated Hospital of China Medical University Shenyang 110001 China Center of Laboratory Technology and Experimental Medicine China Medical University Shenyang110001 China Department of Obstetric and Gynecology Shengjing Hospital China Medical University Shenyang 110004 China

Background and objective Heparanase has been thought to be a good molecular marker of tumor,and the heparanase expression level was correlated closely with tumor metastasis. In this study,we investigate the effects of heparanase on angiogenesis and lymphangiogenesis of lung cancer and the relationship between heparanase expression and vascular endothelial growth factor (VEGF),vascular endothelial growth factor-C (VEGF-C). Methods Immunohistochemistry was used to detect the expression of heparanase,VEGF,VEGF-C protein and microvascular density (MVD),lymphatic vessel density (LVD) in 115 cases of non-small cell lung cancer (NSCLC) and 45 cases of adjacent normal tissue samples. Results Our results showed that heparanase expression was significantly increased in 91 (79.13%) of the 115 cases and correlated with lymph node metastasis (node positive rate 87.0%; node negative rate 36.8%; P=0.003). Heparanase positive expression cases have significantly higher concentration of microvascular density (MVD) and lymphatic vessel density (LVD) as compared with heparanase negative expression cases (P<0.01,P<0.01,respectively),heparanase expression was significantly correlated with VEGF,VEGF-C expression in NSCLC. Conclusion Heparanase overexpression was associated with angiogenesis and lymphangiogenesis of lung cancer,targeting of heparanase may represent a significant therapeutic potential for lung cancer.

关键词：肺癌血管发生治疗方法疗效

CD20阳性的结外鼻型NK/T细胞淋巴瘤一例

在线全文

学校读者我要写书评

暂无评论

中华病理学杂志 2019年第5期48卷 404-406页

作者：朱桂香张清富邱雪杉中国医科大学附属第一医院病理科暨基础医学院病理学教研室沈阳110001

报道1例发生于鼻腔鼻窦部的CD20阳性的结外鼻型NK/T细胞淋巴瘤(extranodal natural killer/T-celllymphoma,nasal type,ENKTCL)□患者女,41岁。以鼻塞为主要表现,免疫表型:***3弥漫强阳性表达,CD56.T细胞胞质内抗原(TIA)1、CD2,bcl-6及bcl-2弥漫阳性表达,EB病毒编码的小RNA(EBER)原位杂交阳性,PAX5、CD99、CD30、CD5、CD7、CD79a及CD10均为阴性,Ki-67阳性指数约85%。基因检测结果示TCRy及IgH基因重排均为阴性。诊断CD20阳性的ENKTCL需结合组织形态学、免疫组织化学.EBER及基因重排等多种检测CD20阳性的ENKTCL可能为治疗提供了靶点,具有潜在的治疗意义。

关键词：鼻型NK/T细胞淋巴瘤阳性表达 CD20 结外 IgH基因重排免疫组织化学 EBER 检测结果

Clinical Implications of HER-2 and P53 in Taxane-Based and Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Clinical Oncology 2008年第6期5卷 424-428页

作者： Xiaolan Wang Fan Yao Nan Liu Yunfei Wu Xinyu Zheng Jiguang Li Caigang Liu xueshan qiu Feng Jin Department of Surgical Oncology Department of General Surgery Department of Pathology the First Hospital of China Medical University Shenyang 110001 Liaoning Province. China.

OBJECTIVE To evaluate the predictive value of humanepidermal growth factor receptor-2 (HER-2) and P53 in taxane-based and anthracycline-based neoadjuvant chemotherapy (NAC)in breast ***-two patients with breast cancer wereincluded in this ***-two patients were treated withtaxane-based (taxane group) and 40 with anthracycline-based(anthracycline group).ER,PR,c-erbB2 and P53 were detected byimmunohistochemistry staining before NAC,and FluorescenceIn Situ Hybridization(FISH) was used to detect the HER-2 geneamplification for the cases with the expression of c-erbB2 proteinas (++) or (+++).The efficacy of the regimens was evaluated *** In the anthracycline group,objective response (OR)was observed in 30 out of 40 patients (75%),whereas no response(NR) was observed in 10 patients (25%).In the taxane group,ORwas observed in 15 patients out of 22 patients (68.2%),whereasNR was observed in 7 patients (31.8%).HER-2-negative status wascorrelated with a high OR in both taxane-based and anthracycline-based NAC (P = 0.023 and P = 0.029),whereas P53-negative statuswas correlated with high OR rate in anthracycline-based NAC (P= 0.041).The significant difference of the CR rates was observedbetween the patients took4 cycles NAC (4.65% vs.21.05%,P<0.05).CONCLUSION The patients with HER-2 gene non-amplicationmay be sensitive to both taxane-based and anthracycline-basedchemotherapy;the patients without P53 overexpression maysuitable to select anthracycline-based chemotherapy;and properincreased NAC cycles may increase CR rates.

关键词： breast neoplasms HER-2 P53 taxane.

单切口胸腔镜手术切除肺炎性肌纤维母细胞瘤1例

在线全文

学校读者我要写书评

暂无评论

中国微创外科杂志 2016年第5期16卷 475-477,480页

作者：张军韩立波邱雪杉中国医科大学附属第一医院肿瘤研究所肿瘤分子靶向治疗研究室沈阳110001 中国医科大学附属第一医院中国医科大学肺癌中心沈阳110001 中国医科大学病理学教研室沈阳110001

2014年8月,对肺右下叶2 cm结节施行单切口胸腔镜亚肺叶切除术,术后病理诊断为肺炎性肌纤维母细胞瘤(inflammatory myofibroblastic tumor,IMT),随访1年余,无复发、转移。

关键词：肺肿瘤炎性肌纤维母细胞瘤单切口胸腔镜手术不断肌肉、不断肋骨、胸部微创小切口手术

在线全文

学校读者我要写书评

暂无评论

miRNA的研究进展

中国当代医药 2010年第19期17卷 14-16页

作者：邱悦邱雪杉中国医科大学临床医学系七年制辽宁沈阳110000 中国医科大学基础医学院辽宁沈阳110000

microRNA又称miRNA,是真核生物细胞中固有的一类不编码蛋白的小分子RNA。生物体中,miRNA能够转录后调控基因的表达,影响着几乎所有的信号通路,参与多种生理病理过程,在肿瘤的发生和发展中也发挥了重要的调节作用。研究miRNA与肿瘤的关... 详细信息

microRNA又称miRNA,是真核生物细胞中固有的一类不编码蛋白的小分子RNA。生物体中,miRNA能够转录后调控基因的表达,影响着几乎所有的信号通路,参与多种生理病理过程,在肿瘤的发生和发展中也发挥了重要的调节作用。研究miRNA与肿瘤的关系是近年来备受关注的热点之一,其影响肿瘤发生和发展的作用机制将为肿瘤的诊断和治疗提供新的思路。

关键词：微小RNA 肿瘤基因调控靶基因

Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer(RATICAL):a nationwide multicenter retrospective study

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2024年第9期44卷 992-1004页

作者： Lin Li Wencai Li ChunyanWu Yanfeng Xi Lei Guo Yuan Ji Lili Jiang Ji Li Jingping Yun Gang Chen Yuan Li Yueping Liu DianbinMu Yuchen Han Leina Sun Qingxin Xia Xiaodong Teng Nanying Che WeiWu xueshan qiu Chao Liu Xiaochu Yan Daiqiang Li Zhihong Zhang ZheWang Yujun Li ZhengWang Lingchuan Guo Xiu Nie Jingshu Geng Jianhua Zhou Jianming Ying Department of Pathology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking UnionMedical CollegeBeijingP.R.China Department of Pathology the First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China Department of Pathology Shanghai Pulmonary HospitalSchool of MedicineTongji UniversityShanghaiP.R.China Department of Pathology Cancer Hospital Affiliated to Shanxi Medical UniversityShanxi Province Cancer HospitalShanxi Hospital Affiliated to Cancer HospitalChinese Academy of Medical SciencesTaiyuanShanxiP.R.China Department of Pathology Zhongshan HospitalFudan UniversityShanghaiP.R.China Department of Pathology West China Hospital of Sichuan UniversityChengduSichuanP.R.China Department of Pathology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingP.R.China Department of Pathology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Pathology Fujian Cancer HospitalFujian Medical University Cancer HospitalFuzhouFujianP.R.China Department of Pathology Department of OncologyFudan University Cancer CenterShanghaiMedical College of Fudan UniversityShanghaiP.R.China Department of Pathology The Fourth Hospital of Hebei Medical UniversityShijiazhuangHebeiP.R.China Department of Pathology Shandong Cancer HospitalJinanShandongP.R.China Department of Pathology Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghaiP.R.China Department of Pathology Tianjin Medical University Cancer Institute and HospitalTianjinP.R.China Department of Pathology the Affiliated Cancer Hospital of Zhengzhou UniversityHenan Provincial Cancer HospitalZhengzhouHenanP.R.China Department of Pathology the First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiangP.R.China Department of Pathology Bei

Background:Anaplastic lymphoma kinase(ALK)test in advanced non-small cell lung cancer(NSCLC)can help physicians provide target therapies for patients harboring ALK gene *** study aimed to investigate the real-world test patterns and positive rates of ALK gene rearrangements in advanced ***:In this real-world study(ChiCTR2000030266),patientswith advanced NSCLC who underwent an ALK rearrangement test in 30 medical centers in China between October 1,2018 and December 31,2019 were retrospectively *** training was conducted before the study was *** controls were performed at participating centers using immunohistochemistry(IHC)-*** positive ALK gene rearrangement rate and consistency rate were *** associated clinicopathological characteristics of ALK gene rearrangement were investigated as ***:The overall ALK gene rearrangement rate was 6.7%in 23,689 patients with advanced NSCLC and 8.2%in 17,436 patients with advanced lung *** quality control analysis of IHC-VENTANA-D5F3 revealed an intrahospital consistency rate of 98.2%(879/895)and an inter-hospital consistency rate of 99.2%(646/651).IHC-VENTANA-D5F3 was used in 53.6%,real-time polymerase chain reaction(RT-PCR)in 25.4%,next-generation sequencing(NGS)in 18.3%,and fluorescence in-situ hybridization(FISH)in 15.9%in the adenocarcinoma *** specimens tested with multiple methods,the consistency rates confirmed by IHC-VENTANA-D5F3 were 98.0%(822/839)for FISH,98.7%(1,222/1,238)forNGS,and 91.3%(146/160)for *** overall ALK gene rearrangement rateswere higher in females,patients of≤35 years old,never smokers,tumor cellularity of>50,and metastatic specimens used for testing in the total NSCLC population and adenocarcinoma subgroup(all P<0.05).Conclusions:This study highlights the real-world variability and challenges of ALK test in advanced NSCLC,demonstrating a predominant use of IHCVENTANA-D5F3 with high co

关键词： anaplastic lymphoma kinase diagnosis gene fusion non-small cell lung cancer